Flexible Electronics News

Dyadic, VTT Developing Efficient Production Method for COVID-19 Vaccines

Advances have been made to develop a new production platform in the industrialized C1 host cell.

Author Image

By: Anthony Locicero

Copy editor, New York Post

Over the last three years, Dyadic and VTT have developed a more efficient and lower cost alternative to produce therapeutic proteins, vaccines and valuable metabolites.    The method is based on exploiting the Thermothelomyces heterothallica C1 fungal strain.    The partners are now developing a new production method for a SARS-CoV-2 coronavirus vaccine.    Currently, the BioPharmaceutical industry is producing therapeutic proteins mainly in the CHO (Chinese hamster ovary) cell syste...

Continue reading this story and get 24/7 access to Ink World magazine for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Ink World magazine Newsletters